Les Newsletters de Stop-Tabac.ch
15 juillet 2014
- E-Cigarette: UK Parliament summary note
- China's e-cigarette inventor fights for financial rewards
- Cultural production of ignorance provides rich field for study
- Youtube; the profile of vapers and how e-cigarettes should be regulated (JF Etter)
- Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study
- Chattez avec un médecin tabacologue
Electronic cigarettes produce a vapour typically containing nicotine, which users inhale. There is debate about their potential role in tobacco smoking reduction and cessation. This POSTnote summarises the evidence on the safety and quality of electronic cigarettes, explores some of the social issues raised and reviews current UK and EU regulation.
http://www.parliament.uk/briefing-papers/POST-PN-455/electronic-cigarettes (03 02 2014)
(15 07 2014)
The Chinese inventor who dreamed up the electronic cigarette in a nicotine-induced vision says that despite its global popularity, copycat versions and legal disputes mean he has battled to cash in on his creation.
"Smoking is the most unhealthy thing in people's everyday lives.... I've made a big contribution to society," said Hon Lik, 57, in a cramped office in Beijing, sending tobacco-scented smoke into the air as he puffed on a battery-powered pipe.
"But I don't live like a rich person, because of all the troubles our company has faced." Read more...:
http://www.foxnews.com/world/2013/10/01/china-e-cigarette-inventor-fights-for-financial-rewards/ (04 10 2013)
(15 07 2014)
Robert Proctor is one of the world's leading experts in agnotology, a neologism signifying the study of the cultural production of ignorance.
Robert Proctor doesn't think ignorance is bliss. He thinks that what you don't know can hurt you. And that there's more ignorance around than there used to be, and that its purveyors have gotten much better at filling our heads with nonsense.
Proctor, a professor of the history of science at Stanford, is one of the world's leading experts in agnotology, a neologism signifying the study of the cultural production of ignorance. It's a rich field, especially today when whole industries devote themselves to sowing public misinformation and doubt about their products and activities.
The tobacco industry was a pioneer at this. read more...
http://www.latimes.com/business/la-fi-hiltzik-20140307,0,1622098.column#axzz2vdthQum3 (11 03 2014)
(15 07 2014)
http://www.youtube.com/watch?v=kqcLwAaW7jg (16 10 2013)
(15 07 2014)
Objective To compare the risk of suicide, self harm, and depression in patients prescribed varenicline or bupropion with those prescribed nicotine replacement therapy.
Design Prospective cohort study within the Clinical Practice Research Datalink.
Setting 349 general practices in England.
Participants 119 546 men and women aged 18 years and over who used a smoking cessation product between 1 September 2006 and 31 October 2011. There were 81 545 users of nicotine replacement products (68.2% of all users of smoking cessation medicines), 6741 bupropion (5.6%), and 31 260 varenicline (26.2%) users.
Main outcome measures Outcomes were treated depression and fatal and non-fatal self harm within three months of the first smoking cessation prescription, determined from linkage with mortality data from the Office for National Statistics (for suicide) and Hospital Episode Statistics data (for hospital admissions relating to non-fatal self harm). Hazard ratios or risk differences were estimated using Cox multivariable regression models, propensity score matching, and instrumental variable analysis using physicians' prescribing preferences as an instrument. Sensitivity analyses were performed for outcomes at six and nine months.
Results We detected 92 cases of fatal and non-fatal self harm (326.5 events per 100 000 person years) and 1094 primary care records of treated depression (6963.3 per 100 000 person years). Cox regression analyses showed no evidence that patients prescribed varenicline had higher risks of fatal or non-fatal self harm (hazard ratio 0.88, 95% confidence interval 0.52 to 1.49) or treated depression (0.75, 0.65 to 0.87) compared with those prescribed nicotine replacement therapy. There was no evidence that patients prescribed bupropion had a higher risk of fatal or non-fatal self harm (0.83, 0.30 to 2.31) or of treated depression (0.63, 0.46 to 0.87) compared with patients prescribed nicotine replacement therapy. Similar findings were obtained using propensity score methods and instrumental variable analyses.
Conclusions There is no evidence of an increased risk of suicidal behaviour in patients prescribed varenicline or bupropion compared with those prescribed nicotine replacement therapy. These findings should be reassuring for users and prescribers of smoking cessation medicines.
BMJ 2013;347:f5704 (Published 11 October 2013)
Kyla H Thomas, Richard M Martin, Neil M Davies, Chris Metcalfe, Frank Windmeijer, and David Gunnell
Note: Open Access. Full-text PDF freely available from link immediately above.
No Increased Risk of Suicide in Patients Using Smoking Cessation Drugs
http://www.sciencedaily.com/releases/2013/10/131010205327.htm (18 10 2013)
(15 07 2014)